Nanny doesn't always know best when it comes to Aim

Anybody who invests in companies listed on the Aim market will no doubt be elated that from 5th August these shares will be eligible to be held in tax free ISAS. There's a great article written in today's Sunday Telegraph by Tom Stevenson that echoes my sentiments entirely:-

"Nanny doesn't always know best when it comes to Aim"

http://www.telegraph.co.uk/finance/comment/tom-stevenson/10205683/Nanny-doesnt-always-know-best-when-it-comes-to-Aim.html

A good balanced article I would suggest. He's quite right that a large number of companies listed on Aim are not worth a second glance, but if you're a stock picker with a reasonable eye for sifting out the potential disasters from the possible winners then it is an exciting market with opportunities to multi-bag your money.

Is Aim listed Angle (AGL) one to stick into an ISA?

I've mentioned before that this is a speculative investment for me, and full year results will be released on Wednesday of this week. I'm not expecting the figures to be impressive at this stage in it's development, but I will be looking carefully at the narrative.

News to date has given cause for encouragement, and on Thursday 25th July they released news relating to a positive evaluation of the Parsortix System from the Cancer Research UK's Paterson Institute for Cancer Research.

Whilst I won't pretend to understand  the significance of the Parsortix System being "Cell marker (epitope) independent", I am encouraged to read the comments from

The Paterson's Genomics Group Leader and Deputy, Clinical & Experimental Pharmacology, Dr Ged Brady, who commented:

"We see great promise in the Parsortix system with the possibility that it may help broaden our understanding of cancer patient blood borne biomarkers which may in turn eventually help us guide and improve therapy. The major attractions for us are the potential for the system to deliver an increased range and number of CTCs along with simplicity of execution. Initial positive results have resulted in the inclusion of the Parsortix device in our ongoing efforts to deliver personalised medicine."

It's incredibly difficult to say with any certainty what lies ahead for Angle. How much additional funding will they require and how will it be raised? how long will it be before we see significant sales of this device? etc, but if the Parsortix System does live up to it's promises then potentially it could be a very bright future for investors, although I might add the caveat that it's still early days relatively speaking!

I look forward to Wednesday with interest, and as ever no advice is intended or given.